Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionVEXMX - Vanguard Extended Market Index Fund Investor Shares
Latest Disclosed Ownership1,287,998 shares
Latest Disclosed Value $ 31,890,830
VEXMX - Vanguard Extended Market Index Fund Investor Shares reports 3.68% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - VEXMX - Vanguard Extended Market Index Fund Investor Shares filed a NPORT-P form disclosing ownership of 1,287,998 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $31,890,830 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 1,242,293 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 3.68% during the quarter. The current value of the position is $40,559,057 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP CATALYST PHARMAC EC US14888U1016 1,287,998 45,705 3.68 31,891 9.98 0.0391
2026-02-26 2025-12-31 NP CATALYST PHARMAC EC US14888U1016 1,242,293 13,317 1.08 28,995 19.76 0.0353
2025-11-25 2025-09-30 NP CATALYST PHARMAC EC US14888U1016 1,228,976 -542,830 -30.64 24,211 -37.03 0.0289
2025-08-27 2025-06-30 NP CATALYST PHARMAC EC US14888U1016 1,771,806 60,552 3.54 38,448 -7.35 0.0340
2025-05-28 2025-03-31 NP CATALYST PHARMAC EC US14888U1016 1,711,254 5,116 0.30 41,498 16.54 0.0408
2025-02-28 2024-12-31 NP CATALYST PHARMAC EC US14888U1016 1,706,138 36,002 2.16 35,607 7.24 0.0320
2024-11-26 2024-09-30 NP CATALYST PHARMAC EC US14888U1016 1,670,136 -54,528 -3.16 33,202 24.28 0.0309
2024-08-27 2024-06-30 NP CATALYST PHARMAC EC US14888U1016 1,724,664 64,095 3.86 26,715 0.93 0.0268
2024-05-29 2024-03-31 NP CATALYST PHARMAC EC US14888U1016 1,660,569 192,820 13.14 26,469 7.28 0.0256
2024-02-29 2023-12-31 NP CATALYST PHARMAC EC US14888U1016 1,467,749 0 0.00 24,673 0.00 0.0254
2024-02-29 2023-12-31 NP CATALYST PHARMAC EC US14888U1016 1,467,749 114,991 8.50 24,673 56.02 0.0254
2023-11-28 2023-09-30 NP CATALYST PHARMAC EC US14888U1016 1,352,758 44,884 3.43 15,814 -10.04 0.0187
2023-08-28 2023-06-30 NP CATALYST PHARMAC EC US14888U1016 1,307,874 9,655 0.74 17,578 -18.34 0.0200
2023-05-26 2023-03-31 NP CATALYST PHARMAC EC US14888U1016 1,298,219 32,889 2.60 21,524 -8.54 0.0257
2023-03-01 2022-12-31 NP CATALYST PHARMAC EC US14888U1016 1,265,330 41,394 3.38 23,535 49.88 0.0298
2022-11-29 2022-09-30 NP CATALYST PHARMAC EC US14888U1016 1,223,936 -74,046 -5.70 15,703 72.60 0.0206
2022-08-29 2022-06-30 NP CATALYST PHARMAC EC US14888U1016 1,297,982 3,326 0.26 9,099 -15.23 0.0117
2022-05-31 2022-03-31 NP CATALYST PHARMAC EC US14888U1016 1,294,656 -42,550 -3.18 10,733 18.56 0.0109
2022-03-01 2021-12-31 NP CATALYST PHARMAC EC US14888U1016 1,337,206 31,275 2.39 9,053 30.79 0.0083
2021-11-29 2021-09-30 NP CATALYST PHARMAC EC US14888U1016 1,305,931 -126,704 -8.84 6,921 -15.98 0.0063
2021-08-30 2021-06-30 NP CATALYST PHARMAC EC US14888U1016 1,432,635 -31,028 -2.12 8,238 22.08 0.0072
2021-06-01 2021-03-31 NP CATALYST PHARMAC EC US14888U1016 1,463,663 0 0.00 6,747 38.03 0.0064
2021-03-01 2020-12-31 NP CATALYST PHARMAC EC US14888U1016 1,463,663 55,695 3.96 4,889 16.91 0.0051
2020-11-27 2020-09-30 NP CATALYST PHARMAC EC US14888U1016 1,407,968 -24,430 -1.71 4,182 -36.81 0.0056
2020-08-31 2020-06-30 NP CATALYST PHARMAC EC US14888U1016 1,432,398 35,152 2.52 6,618 23.02 0.0095
2020-06-01 2020-03-31 NP CATALYST PHARMAC EC US14888U1016 1,397,246 -256 -0.02 5,379 2.65 0.0101
2020-02-28 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 1,397,502 8,056 0.58 5,241 -28.97 0.0070
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,389,446 1,389,446 7,378 0.0106
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.